PDCD1 and neoplasm: The results of our murine study showed that the combination anti-PD1/IGF1R treatment significantly reduced the tumor burden by 40% compared to IGF1R inhibitor and 34% with anti-PD-1 treatments (Figure 4B) and achieved a higher survival rate compared to the anti-PD1 treatment alone (Figures 4C, D).